Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.61 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.49 |
| ▸ | MGAM | O43451 | 2/20 | 0.49 |
| ▸ | SI | P14410 | 2/20 | 0.49 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.49 |
| ▸ | SNCA | P37840 | 2/20 | 0.49 |
| ▸ | MIF | P14174 | 1/20 | 0.49 |
| ▸ | BACE1 | P56817 | 3/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29763068 | 0.86 | ALDH1A1 (0.64) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL344639 | 0.86 | ALDH1A1 (0.64) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL344638 | 0.86 | ALDH1A1 (0.64) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL345486 | 0.82 | GABRA3 (0.51) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL345485 | 0.82 | GABRA3 (0.51) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL29065213 | 0.80 | CHRNA7 (0.61) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL29065212 | 0.80 | CHRNA7 (0.61) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL10321326 | 0.78 | GABRA3 (0.70) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL10321325 | 0.78 | GABRA3 (0.70) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL31501090 | 0.78 | GABRA3 (0.70) | ALDH1A1MAPTKDM4EMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120087904-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC (US) | 2012-04-12 | — | — | US | claimed |
| US-20120087947-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING DERMATITIS | AmDerma Pharmaceuticals, LLC (US) | 2012-04-12 | — | — | US | claimed |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES (ES) | 2012-01-19 | — | — | US | claimed |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES (ES) | 2011-10-20 | — | — | US | claimed |
| US-20110237555-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF ROSACEA | ACTION MEDICINES (ES) | 2011-09-29 | — | — | US | claimed |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | SANCHEZ PEDRO CUEVAS | 2011-06-23 | — | — | US | claimed |
| US-20120087904-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | AmDerma Pharmaceuticals, LLC (US) | 2012-04-12 | — | — | US | disclosed |
| US-20120087947-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING DERMATITIS | AmDerma Pharmaceuticals, LLC (US) | 2012-04-12 | — | — | US | disclosed |
| US-8101660-B2 | Use of 2,5-dihydroxybenzene compounds and derivatives for the treatment of skin cancer | AmDerma Pharmaceuticals, LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ACTION MEDICINES (ES) | 2012-01-19 | — | — | US | disclosed |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | ACTION MEDICINES (ES) | 2011-10-20 | — | — | US | disclosed |
| US-20110237555-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF ROSACEA | ACTION MEDICINES (ES) | 2011-09-29 | — | — | US | disclosed |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | SANCHEZ PEDRO CUEVAS | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120087904-A1 | Use Of 2,5-Dihydroxybenzene Compounds And Derivatives For The Treatment Of Skin Cancer | CYP8B1, CYP26B1, CYP24A1 | ALDH1A1 101/4885MAPT 3634/4885KDM4E 540/4885 |
| US-20120015912-A1 | USE OF 2,5-DIHYDROXYBENZENE FOR THE TREATMENT OF OCULAR DISEASES | ALDH1A2, CRYAB, HSD17B14 | ALDH1A1 408/4885MAPT 917/4885KDM4E 1092/4885 |
| US-20110237555-A1 | USE OF 2,5-DIHYDROXYBENZENE COMPOUNDS AND DERIVATIVES FOR THE TREATMENT OF ROSACEA | CYP8B1, CYP1B1, CYP26B1 | ALDH1A1 15/4885MAPT 2619/4885KDM4E 2246/4885 |
| US-20120087947-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING DERMATITIS | CYP24A1, CYP8B1, CYP26B1 | ALDH1A1 79/4885MAPT 2332/4885KDM4E 1185/4885 |
| US-20110257264-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR TREATING ACTINIC KERATOSIS | CYP8B1, DERA, KRT18 | ALDH1A1 60/4885MAPT 1031/4885KDM4E 1371/4885 |
| US-20110152222-A1 | USE OF 2,5-DIHYDROXYBENZENE DERIVATIVES FOR THE TREATMENT OF ARTHRITIS AND PAIN | CYP8B1, CYP26B1, UGT2B7 | ALDH1A1 75/4885MAPT 2962/4885KDM4E 1627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.